Mobile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 36-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients with Type 2 Diabetes Mellitus

Update Il y a 4 ans
Reference: EUCTR2007-002515-75

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the LDL-C lowering efficacy of ER niacin/laropiprant (1 to 2g) compared with placebo in patients with Type 2 diabetes.

Inclusion criteria

  • type II diabetes mellitus

Links